Bioventus said today it inked a deal to pick up the U.S. rights for Durolane joint lubrication from Galderma for an undisclosed amount.
Galderma’s Durolane is a single-injection, hyaluornic acid product designed to lubricate joints to treat pain associated with knee osteoarthritis, Durham, N.C.-based Bioventus said.
“Bringing Durolane to the US is the next step in our strategy to offer osteoarthritis patients more choices for pain relief. As a single-injection HA, it has improved the lives of more than one million people worldwide and we are pleased to work with Galderma to complete the process of introducing this solution to US patients,” Bioventus CEO Tony Bihl said in a press release
Bioventus said it plans to file a premarket approval application with the FDA early next year as it seeks to bring Durolane to market in the U.S. The company said it owns the international rights to the product and has commercialized it internationally for 15 years.
In September Bioventus said it launched the Exogen ultrasound bone healing system in Saudi Arabia.
The Company’s Exogen is designed to use low-intensity pulsed ultrasound to “help stimulate the body’s natural healing process.” Bioventus touts an 86% healing rate for fractures not healing on their own and 38% faster healing of fresh fractures with use of the device.
